Nelivaptan

Nelivaptan

Nelivaptan

Chemical compound

Nelivaptan (INN)[1] (developmental codename SSR-149,415) is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype.[2] The drug had entered clinical trials for treatment of anxiety and depression.[3] In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.[4]

Quick Facts Clinical data, Routes ofadministration ...

See also

References

  1. [1]
    World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98" (PDF). WHO Drug Information. 21 (4): 341.
  2. [2]
    Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002). "Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders". Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6370–5. Bibcode:2002PNAS...99.6370G. doi:10.1073/pnas.092012099. PMC 122955. PMID 11959912.
  3. [3]
    Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005). "An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders". CNS Drug Reviews. 11 (1): 53–68. doi:10.1111/j.1527-3458.2005.tb00035.x. PMC 6741711. PMID 15867952.
  4. [4]
    "Second-quarter 2008 results" (PDF). Press Release. Sanofi-Aventis. 2008-07-31. Archived from the original (PDF) on 2008-12-06. Retrieved 2009-06-10. It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist).


Stub icon

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Nelivaptan, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.